Innovation Endeavors (RBOT) cuts Vicarious Surgical stake to 3.4%

Rhea-AI Filing Summary

Innovation Endeavors III and Dror Berman filed an amended Schedule 13D to update their ownership in Vicarious Surgical Inc. Class A common stock. They report beneficial ownership of 221,038 shares, or 3.4% of the class, based on 6,470,228 shares outstanding as of March 16, 2026.

The filing shows that Innovation Endeavors made a series of open market sales from March 20 to April 6, 2026 at weighted average prices between $0.70 and $1.06 per share. As a result, the reporting persons state they ceased to be beneficial owners of more than five percent of the Class A common stock on April 6, 2026.

Insights

Equity ownership analyst

Venture holder steps down from 5%+ status after steady RBOT share sales.

Innovation Endeavors III, with managing partner Dror Berman, now reports 221,038 Vicarious Surgical Class A shares, equal to 3.4% of the class based on 6,470,228 shares outstanding as of March 16, 2026.

The filing details multiple open market transactions between March 20 and April 6, 2026 at weighted average prices from $0.70 to $1.06 per share. This sequence reduces their stake below the 5% reporting threshold, which often marks a shift from large-block holder status to a smaller, more flexible position.

The change may alter the company’s large-holder landscape, as the investors explicitly note they ceased to be beneficial owners of more than five percent on April 6, 2026. Future ownership updates, if any, would likely appear through subsequent beneficial ownership reports or other SEC disclosures.

Key Figures

Beneficial ownership: 221,038 shares Ownership percentage: 3.4% Shares outstanding: 6,470,228 shares +4 more

7 metrics

Beneficial ownership 221,038 shares Class A common stock held by Innovation Endeavors III

Ownership percentage 3.4% Percent of Class A shares beneficially owned

Shares outstanding 6,470,228 shares Class A common stock outstanding as of March 16, 2026

Sale price range (high) $1.06 per share Weighted average sales price on March 20, 2026

Sale price range (low) $0.70 per share Weighted average sales price on March 27, 2026

Single-day sale 53,868 shares Aggregate open market sales on April 2, 2026

Largest disclosed sale day 136,682 shares Aggregate open market sales on April 6, 2026

Key Terms

beneficially owned, Schedule 13D, open market transactions, weighted average sales price, +2 more

6 terms

beneficially owned financial

"percentages of the shares of Class A common stock beneficially owned by such Reporting Person"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Schedule 13D regulatory

"previously filed a statement on Schedule 13D to report the acquisition"

A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.

open market transactions financial

"sold an aggregate of 10,774 shares in open market transactions at prices"

Open market transactions are the buying and selling of a company’s shares or other securities conducted on public exchanges or through the wider market rather than through private deals or negotiated placements. They matter to investors because these trades change supply and demand in real time—like shoppers affecting a store’s inventory—and so can move prices, signal management or investor sentiment, affect liquidity, and alter ownership stakes that influence future returns and risk.

weighted average sales price financial

"weighted average sales price of $1.06 per share"

definitive proxy statement regulatory

"as reported in the Issuer's definitive proxy statement, filed with the SEC"

A Definitive Proxy Statement is a detailed document that a company sends to its shareholders before a big meeting, like voting on important decisions. It explains what's being voted on and gives important information so shareholders can make informed choices. It matters because it helps shareholders understand and participate in key company decisions.

sole or shared power financial

"sole or shared power to vote or direct the vote and sole or shared power to dispose"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)

Vicarious Surgical Inc.

(Name of Issuer)

Class A Common Stock, par value $0.0001 per share

(Title of Class of Securities)

92561V208

(CUSIP Number)

Rebecca Lucia
c/o Innovation Endeavors, 1845 El Camino Real
Palo Alto, CA, 94306
(650) 644-6822

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

04/02/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 92561V208

1

Name of reporting person

Innovation Endeavors III LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 221,038.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 221,038.00

11

Aggregate amount beneficially owned by each reporting person

221,038.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

3.4 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP Number(s): 92561V208

1

Name of reporting person

Dror Berman

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 221,038.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 221,038.00

11

Aggregate amount beneficially owned by each reporting person

221,038.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

3.4 %

14

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Class A Common Stock, par value $0.0001 per share
(b)	Name of Issuer: Vicarious Surgical Inc.
(c)	Address of Issuer's Principal Executive Offices: 78 Fourth Avenue, Waltham, MASSACHUSETTS , 02451.
Item 1 Comment: This Amendment No. 1 (this "Amendment No. 1" or this "Schedule 13D/A") amends and supplements the statement on Schedule 13D originally filed with the Securities and Exchange Commission (the "SEC") on September 28, 2021 (the "Statement") by the Reporting Persons. Unless otherwise defined herein, capitalized terms used in this Amendment No. 1 shall have the meanings ascribed to them in the Statement. Unless amended or supplemented below, the information in the Statement remains unchanged.
Item 5.	Interest in Securities of the Issuer
(a)	Rows 11 and 13 of each Reporting Person's cover page to this Schedule 13D set forth the aggregate number of shares of Class A common stock and percentages of the shares of Class A common stock beneficially owned by such Reporting Person and are incorporated by reference. The percentage set forth in each row 13 is based upon 6,470,228 shares of Class A common stock outstanding as of March 16, 2026, as reported in the Issuer's definitive proxy statement, filed with the SEC on March 23, 2026. The Reporting Persons' beneficial ownership of the Issuer's securities includes 221,038 shares of Class A common stock directly held by Innovation Endeavors. Mr. Berman is a managing partner at Innovation Endeavors and shares voting and investment authority over the shares held by Innovation Endeavors.
(b)	Rows 7 through 10 of each Reporting Person's cover page to this Schedule 13D set forth the number of shares of Class A common stock as to which such Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition and are incorporated by reference.
(c)	Except as set forth below, none of the Reporting Persons has effected any transactions with respect to the securities of the Issuer during the past sixty days. On March 20, 2026, Innovation Endeavors sold an aggregate of 10,774 shares in open market transactions at prices ranging from $1.05 to $1.11 (weighted average sales price of $1.06 per share). On March 23, 2026, Innovation Endeavors sold an aggregate of 25,000 shares in open market transactions at prices ranging from $1.00 to $1.05 (weighted average sales price of $1.00 per share). On March 24, 2026, Innovation Endeavors sold an aggregate of 1,001 shares in open market transactions at prices ranging from $0.95 to $1.00 (weighted average sales price of $0.95 per share). On March 25, 2026, Innovation Endeavors sold an aggregate of 25 shares in an open market transaction at a price of $1.00 per share. On March 26, 2026, Innovation Endeavors sold an aggregate of 3,013 shares in open market transactions at prices ranging from $0.85 to $1.00 (weighted average sales price of $0.91 per share). On March 27, 2026, Innovation Endeavors sold an aggregate of 1,000 shares in open market transactions at prices ranging from $0.70 to $0.72 (weighted average sales price of $0.70 per share). On March 30, 2026, Innovation Endeavors sold an aggregate of 4,595 shares in open market transactions at prices ranging from $0.80 to $0.81 (weighted average sales price of $0.80 per share). On March 31, 2026, Innovation Endeavors sold an aggregate of 1,449 shares in open market transactions at prices ranging from $0.71 to $0.83 (weighted average sales price of $0.76 per share). On April 1, 2026, Innovation Endeavors sold an aggregate of 1,487 shares in open market transactions at prices ranging from $0.65 to $0.88 (weighted average sales price of $0.80 per share). On April 2, 2026, Innovation Endeavors sold an aggregate of 53,868 shares in open market transactions at prices ranging from $0.72 to $0.83 (weighted average sales price of $0.78 per share). On April 6, 2026, Innovation Endeavors sold an aggregate of 136,682 shares in open market transactions at prices ranging from $0.78 to $0.85 (weighted average sales price of $0.82 per share).
(d)	No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, the securities beneficially owned by any of the Reporting Persons.
(e)	The Reporting Persons ceased to be the beneficial owners of more than five percent of the Class A common stock on April 6, 2026.
Item 7.	Material to be Filed as Exhibits.
	Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit 1 to the Reporting Persons' Schedule 13D filed with the SEC on September 28, 2021).

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Innovation Endeavors III LP

Signature:	/s/ Dror Berman
Name/Title:	By Dror Berman, Managing Partner
Date:	04/06/2026

Dror Berman

Signature:	/s/ Dror Berman
Name/Title:	Dror Berman
Date:	04/06/2026

FAQ

What ownership stake in Vicarious Surgical (RBOT) does Innovation Endeavors now report?

Innovation Endeavors III and Dror Berman report beneficial ownership of 221,038 shares of Vicarious Surgical Class A common stock, representing 3.4% of the class. This percentage is based on 6,470,228 shares outstanding as of March 16, 2026, per the issuer’s proxy statement.

When did Innovation Endeavors cease to be a 5% beneficial owner of Vicarious Surgical (RBOT)?

The investors state they ceased to be beneficial owners of more than five percent of Vicarious Surgical’s Class A common stock on April 6, 2026. This date reflects the impact of their recent open market sales disclosed in the amended Schedule 13D filing.

How many Vicarious Surgical (RBOT) shares are outstanding for this Schedule 13D/A calculation?

The reported 3.4% ownership is calculated using 6,470,228 shares of Class A common stock outstanding as of March 16, 2026. That outstanding share figure comes from Vicarious Surgical’s definitive proxy statement filed with the SEC on March 23, 2026.

What trading activity in Vicarious Surgical (RBOT) shares does Innovation Endeavors disclose?

The filing lists several open market sales from March 20 to April 6, 2026. Transaction blocks range from small lots to larger sales, with weighted average prices between $0.70 and $1.06 per share, contributing to the reduced ownership percentage reported.

Who shares voting and investment power over the Vicarious Surgical (RBOT) shares?

The Schedule 13D/A states that Innovation Endeavors directly holds the 221,038 shares, and Dror Berman, as a managing partner, shares voting and investment authority over these shares. Both reporting persons list shared voting and dispositive power over the same share amount.

Does any other party have rights to dividends or sale proceeds from the reported RBOT shares?

The filing notes that no other person is known to have the right to receive, or to direct the receipt of, dividends or proceeds from the sale of the securities beneficially owned by the reporting persons. This clarifies economic interest in the disclosed holdings.